-
Article type: Cover
2001 Volume 50 Issue 6 Pages
Cover18-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Cover
2001 Volume 50 Issue 6 Pages
Cover19-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Mitsuru Adachi, Kenji Minoguchi
Article type: Article
2001 Volume 50 Issue 6 Pages
505-507
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Nobuyuki Miyasaka
Article type: Article
2001 Volume 50 Issue 6 Pages
508-512
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Hideaki Yamasawa, Katsuhisa Oshikawa, Yukihiko Sugiyama
Article type: Article
2001 Volume 50 Issue 6 Pages
513-519
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
Supratast tosilate is a newly developed 'anti-allergic' drug and it has been shown to suppress cytokine production by type-2 helper T cells (Th2) in vitrO. However, it is unclear whether a similar inhibitory effect on Th2 cytokines production is produced iv vitro. To elucidate the actions of the in vivo mechanisms of this drug, we isolated peripheral blood mononuclear cells (PBMCs) from 10 atopic asthmatics treated with supratast tosilate and investigated the capacity for cytokine production ex vivo. Interleukin (IL) -5 production by PBMCs stimulated with the combination of phorbol myristate acetate and ionomycin were reduced significantly 6 or 12 weeks after the treatment with supratast tosilate. In contrast, no significant reduction was seen in IL-4 or Interferon (IFN) -γ production. The peripheral blood eosinophil count and weeks, but no significant difference was sees in total IgE levels. Both morning and evening peak expiratory flow were significantly elevated after 6 weeks. These results suggest that supratast tosilate improves the disease status of bronchial asthma through its ability to inhibit the production Th2 cytokines, at least IL-5, in vivo.
View full abstract
-
Kimihiro Ohkubo, Ryuta Takizawa, Minoru Gotoh, Minoru Okuda
Article type: Article
2001 Volume 50 Issue 6 Pages
520-527
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
A study was conducted in 165 subjects with Japanese cedar pollinosis (JC) to evaluate the switching to the new standardized extract (SE) for patients who are going on specific immunotherapy (SP-IT) with conventional non-standardized extracts, products of Trii Co. or Hollister-Stier Co. Eight of 137 subjects exhibited adverse systemic reactions such as general skin eruption and despnea when JC allergen extract of Hollister-Stier Co. was switched to JC-SE. There were 6 cases where concentration of the extract had to be decreased due to extraordinary late reactions, while none of 28 subjects exhibited adverse side effect, when conventional allergen extract by Torii Pharmaceutical Co. was switched to JC-SE. Careful switching to high concentration of SE is required, because eight cases with adverse side effect were shown in switching to 200 JAU/ml and 2000 JAU/ml. 20 subjects started with SP-IT by JC-SE after spread of JC in the year of 2000 exhibited no adverse side effects in our protocol.
View full abstract
-
Masaru Kagami, Hisao Tomioka, Takuya Nakazawa, Shoji Yoshida
Article type: Article
2001 Volume 50 Issue 6 Pages
528-534
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
We conducted a questionnaire survey on the onset time and frequency of asthmatic symptoms in adults with bronchial asthma who were regular clinic attendees in 17 sites in Chiba Prefecture, and analyzed 513 respondents. As a result, the frequency of wheezing was 54.6%, the highest of all symptoms. Feeling of chest discomfort was 32.2%, followed by asthma attack (13.8%), cough (8.7%) and dynpnea (6.8%). Asthmatic symptoms were highest from midnight to early morning, with the peak at aroud 4 o' clock am. The same pattern was seen regardless of the severity and types of asthma. This survey also showed that conventional anti-asthmatic therapies decreased the frequency of nightly asthmatic symptoms from the baseline: 7 times or more per week reduced from 44.9% to 16.1%, 3 times or more per week from 76.8% to 40.4%, and at least once per week from 94.4% to 71.5%. The results suggest that it is important to take another therapeutic strategy, which can administer medications at the appropriate time according to the circadian rhythms in asthmatic patients to better control asthma.
View full abstract
-
Tadao Enomoto, Shigeo Ohnishi, Yoshiro Dake, Takema Sakoda, Yuko Saito ...
Article type: Article
2001 Volume 50 Issue 6 Pages
535-539
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
Caring for oneself against Japanese cedar pollinosis is important as well as receiving medical-care. Although the importance of avoiding pollen is described in the guideline for nasal allergy medical treatment, however, there is no information for effective dust cleaning for the home. This study examined how many cedar pollens were included in indoor dust in order to obtain basic data whether dust removal for cedar pollen is available for pollinosis suffers. As a result, the study found that there were many Japanese cedar pollens in indoor dust even before the pollen seasen. Cedar pollen increased with the increasing number of airborne pollen. The highest number of pollen found in one week was approximately 450 pollens in a square meter of a living room flOOr. The study concluded that cleaning is one of the best way to remove Japanese cedar pollens found in indoor dust.
View full abstract
-
Hiroyasu Muramatsu, Risa Kotajima, Tetsuo Sato
Article type: Article
2001 Volume 50 Issue 6 Pages
540-546
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
Seratrodast, an antagonist to thromboxane A_2 (TXA_2) receptors, is not always effective in patients with bronchial asthma. In fact, some respond definitely to this drug while others not. In the present study, to clarify the predictability of the clinical effects of Seratrodast, we investigated whether there is a correlation between the levels of TXB_2 and 11-DHTXB_2, both of which are metabolites of TXA_2, in urine and sputum taken before the administration and the clinical effects seen after initiation of the treatment. Baseline concentrations of TXA_2 metabolites in urine/sputum were not significantly different between responders and nomresponders. However, 4 cases who had remarkably responded to Seratrodast had significantly higher baseline 11-DHTXB_2 levels than the rest of the patients. These results suggested that bronchial asthma patients with high urinary 11-DHTXB_2 levels could markedly respond to Seratrodast treatment.
View full abstract
-
Junko Sowa, Akiko Tomitaka, Kayoko Suzuki, Kayoko Matsunaga
Article type: Article
2001 Volume 50 Issue 6 Pages
547-550
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Katsuya Fujimori, Eiichi Suzuki, Fumitake Gejyo
Article type: Article
2001 Volume 50 Issue 6 Pages
551-554
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Mayumi Yuge, Yayoi Niimi, Seiji Kawana
Article type: Article
2001 Volume 50 Issue 6 Pages
555-557
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
558-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
559-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
560-563
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
564-567
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
568-585
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
586-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
586-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
587-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
588-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
588-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
589-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
589-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
590-591
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2001 Volume 50 Issue 6 Pages
592-596
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Cover
2001 Volume 50 Issue 6 Pages
Cover20-
Published: June 30, 2001
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS